ReviewVeterinary sciences2022
The Novel Diagnostic Techniques and Biomarkers of Canine Mammary Tumors.
Review in Veterinary sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Integrated Biomarker Assessment for Prognosis in Canine Mammary Carcinomas: Complementary Roles of Serum CA 15-3 and Immunohistochemistry Ki-67, and COX-2.Animals : an open access journal from MDPI · 2026Article
- Article
- Cytologic Grading of Canine Mammary Tumors by Robinson's System Adapted to Romanowsky-Type Rapid Staining: Prognostic Implications.Veterinary clinical pathology · 2026Article
- Estrobolome dysbiosis in canine mammary gland tumors:Frontiers in microbiology · 2026Article
- The role of epigenetic alterations in canine mammary cancer.The Journal of reproduction and development · 2026Review
- Androgen Receptors in Human Breast Cancer and Female Canine Mammary Tumors.Molecules (Basel, Switzerland) · 2025Review
- Low-Invasive Biomarkers of Canine Mammary Tumours.Veterinary medicine and science · 2025Review
- Pseudolaric acid B induces G2/M phase arrest in canine mammary tumor cells by targeting CDK1.Frontiers in veterinary science · 2025Article
- Dysregulated Signaling Pathways in Canine Mammary Tumor and Human Triple Negative Breast Cancer: Advances and Potential Therapeutic Targets.International journal of molecular sciences · 2024Review
- Proteomic analysis of extracellular vesicles derived from canine mammary tumour cell lines identifies protein signatures specific for disease state.BMC veterinary research · 2024Article
- Enhancing electrochemical detection through machine learning-driven prediction for canine mammary tumor biomarker with green silver nanoparticles.Analytical and bioanalytical chemistry · 2024Article
- Nuclear Magnetic Resonance (NMR) Metabolomics: Current Applications in Equine Health Assessment.Metabolites · 2024Review
- The Carnitine Palmitoyltransferase 1A Inhibitor Teglicar Shows Promising Antitumour Activity against Canine Mammary Cancer Cells by Inducing Apoptosis.Pharmaceuticals (Basel, Switzerland) · 2023Article
- SFRP1 Expression is Inversely Associated With Metastasis Formation in Canine Mammary Tumours.Journal of mammary gland biology and neoplasia · 2023Article
- Canine Mammary Neoplasia Induces Variations in the Peripheral Blood Levels of CD20, CD45RA, and CD99.International journal of molecular sciences · 2023Article
- The Importance of Ultrasonography in the Evaluation of Mammary Tumors in Bitches.Animals : an open access journal from MDPI · 2023Review
- GATA-3 expression and its correlation with prognostic factors and survival in canine mammary tumors.Frontiers in veterinary science · 2023Article
- Diagnostic value of carcinoembryonic antigen, cancer antigen 15-3, and cell-free DNA as blood biomarkers in early detection of canine mammary tumor.Journal of circulating biomarkersArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Canine mammary tumors (CMTs) are considered a serious clinical problem in older bitches. Due to the high malignancy rate and poor prognosis, an early diagnosis is essential. This article is a summary of novel diagnostic techniques as well as the main biomarkers of CMTs. So far, CMTs are detected only when changes in mammary glands are clinically visible and surgical removal of the mass is the only recommended treatment. Proper diagnostics of CMT is especially important as they represent a very diverse group of tumors and therefore different treatment approaches may be required. Recently, new diagnostic options appeared, like a new cytological grading system of CMTs or B-mode ultrasound, the Doppler technique, contrast-enhanced ultrasound, and real-time elastography, which may be useful in pre-surgical evaluation. However, in order to detect malignancies before macroscopic changes are visible, evaluation of serum and tissue biomarkers should be considered. Among them, we distinguish markers of the cell cycle, proliferation, apoptosis, metastatic potential and prognosis, hormone receptors, inflammatory and more recent: metabolomic, gene expression, miRNA, and transcriptome sequencing markers. The use of a couple of the above-mentioned markers together seems to be the most useful for the early diagnosis of neoplastic diseases as well as to evaluate response to treatment, presence of tumor progression, or further prognosis. Molecular aspects of tumors seem to be crucial for proper understanding of tumorigenesis and the application of individual treatment options.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.